Impact of COVID-19 on the Diagnosis and Management of Multiple Myeloma: Experience from a Canadian Center.

IF 1.4 4区医学 Q2 Medicine

Revista De Investigacion Clinica-Clinical and Translational Investigation Pub Date : 2022-01-03 DOI:10.24875/RIC.21000347

Victor H Jimenez-Zepeda, Patrick Yau, Douglas Stewart, Jowher Berhan, Carole Chambers, Holly Lee, Jason Tay, Peter Duggan, Sylvia McCulloch, Paola Neri, Nizar Bahlis

{"title":"Impact of COVID-19 on the Diagnosis and Management of Multiple Myeloma: Experience from a Canadian Center.","authors":"Victor H Jimenez-Zepeda, Patrick Yau, Douglas Stewart, Jowher Berhan, Carole Chambers, Holly Lee, Jason Tay, Peter Duggan, Sylvia McCulloch, Paola Neri, Nizar Bahlis","doi":"10.24875/RIC.21000347","DOIUrl":null,"url":null,"abstract":"Background: The impact of coronavirus disease-19 on the management of multiple myeloma (MM) has been recognized. However, the real effect on clinical outcomes remains poorly understood.Objective: We describe a local experience of the management of MM patients and report their outcomes during the current pandemic.Methods: All consecutive symptomatic MM patients seen at our center since 03/20 were evaluated.Results: A cohort of 156 patients diagnosed from 01/19 to 12/20 was analyzed to interrogate differences in presentation patterns. A total of 553 MM patients were seen and/or treated at Tom Baker Cancer Center in the year of 2020. From those, 47.1% (n = 261) were tested for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Sixteen patients tested positive and data are presented. In addition, a decrease of 21.7% in the rate of new smoldering MM/MM diagnosis was observed in 2020 as compared to 2019. Further, an increase in deaths was also observed in 2020.Conclusions: Our study confirms an increase lethality for MM patients infected with SARS-CoV-2. A balance between safety and need for cancer control should be emphasized.","PeriodicalId":49612,"journal":{"name":"Revista De Investigacion Clinica-Clinical and Translational Investigation","volume":"74 1","pages":"16-22"},"PeriodicalIF":1.4000,"publicationDate":"2022-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista De Investigacion Clinica-Clinical and Translational Investigation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.24875/RIC.21000347","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The impact of coronavirus disease-19 on the management of multiple myeloma (MM) has been recognized. However, the real effect on clinical outcomes remains poorly understood.

Objective: We describe a local experience of the management of MM patients and report their outcomes during the current pandemic.

Methods: All consecutive symptomatic MM patients seen at our center since 03/20 were evaluated.

Results: A cohort of 156 patients diagnosed from 01/19 to 12/20 was analyzed to interrogate differences in presentation patterns. A total of 553 MM patients were seen and/or treated at Tom Baker Cancer Center in the year of 2020. From those, 47.1% (n = 261) were tested for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Sixteen patients tested positive and data are presented. In addition, a decrease of 21.7% in the rate of new smoldering MM/MM diagnosis was observed in 2020 as compared to 2019. Further, an increase in deaths was also observed in 2020.

Conclusions: Our study confirms an increase lethality for MM patients infected with SARS-CoV-2. A balance between safety and need for cancer control should be emphasized.

查看原文本刊更多论文

COVID-19对多发性骨髓瘤诊断和治疗的影响:来自加拿大中心的经验

背景:冠状病毒病-19对多发性骨髓瘤(MM)治疗的影响已被认识。然而，对临床结果的真正影响仍然知之甚少。目的:我们描述了MM患者管理的本地经验，并报告了他们在当前大流行期间的结果。方法:对自2003年3月以来在本中心就诊的所有连续出现症状的MM患者进行评估。结果:我们分析了156例于2019年1月1日至2020年12月诊断的患者，以探讨其表现模式的差异。2020年，共有5553名MM患者在Tom Baker癌症中心就诊和/或接受治疗。其中47.1% (n = 261)接受了严重急性呼吸综合征冠状病毒-2 (SARS-CoV-2)检测。16例患者检测呈阳性，并给出数据。此外，与2019年相比，2020年新发阴燃MM/MM诊断率下降了21.7%。此外，2020年死亡人数也有所增加。结论:我们的研究证实了感染SARS-CoV-2的MM患者的死亡率增加。应强调安全性与癌症控制需要之间的平衡。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Revista De Investigacion Clinica-Clinical and Translational Investigation 医学-医学：内科

CiteScore

3.00

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： The Revista de Investigación Clínica – Clinical and Translational Investigation (RIC-C&TI), publishes original clinical and biomedical research of interest to physicians in internal medicine, surgery, and any of their specialties. The Revista de Investigación Clínica – Clinical and Translational Investigation is the official journal of the National Institutes of Health of Mexico, which comprises a group of Institutes and High Specialty Hospitals belonging to the Ministery of Health. The journal is published both on-line and in printed version, appears bimonthly and publishes peer-reviewed original research articles as well as brief and in-depth reviews. All articles published are open access and can be immediately and permanently free for everyone to read and download. The journal accepts clinical and molecular research articles, short reports and reviews. Types of manuscripts: – Brief Communications – Research Letters – Original Articles – Brief Reviews – In-depth Reviews – Perspectives – Letters to the Editor